GLP-1 Insurance Coverage and Prior Authorization, Explained

Getting a GLP-1 covered is rarely a simple "yes" or "no" — it's a paperwork process with its own logic, and most of the frustration comes from not knowing what that process is actually checking for. Here's the structure behind it, not just the complaint about it.

Why prior authorization exists for this drug class specifically

Anti-obesity medications are expensive at scale, and insurers use prior authorization to confirm a prescription meets their coverage policy before paying — a standard mechanism, but one applied unusually aggressively to this class. A review of managed-care considerations for weight-management interventions notes plainly that it remains uncommon for all effective obesity treatments, GLP-1s included, to be covered by insurance at all, and encourages managed-care decision makers to expand access precisely because limited coverage drives worse health outcomes and higher downstream costs¹. That's the tension every prior-authorization request sits inside: the insurer's default posture toward this drug class is skepticism, not routine approval.

What does a GLP-1 prior authorization check for?

Coverage policies vary by plan, but prior-authorization criteria for GLP-1s generally converge on the same handful of checks: a documented BMI above a policy threshold (commonly 30, or 27 with a qualifying comorbidity such as hypertension, type 2 diabetes or sleep apnea), evidence of a prior attempt at lifestyle intervention, and — on many commercial plans — step therapy requiring a cheaper drug to have failed first. None of that is unique to GLP-1s; it mirrors how insurers gate other high-cost drug classes. What is unusual is how often the request is denied anyway even when criteria are met, which is why a documented history and a clinician willing to file (and refile) matter as much as your actual eligibility.

The one federal lever that already exists

For Medicare and Medicaid, first identify the current benefit pathway. Our Medicare, Medicaid and HSA/FSA guide explains the temporary Medicare GLP-1 Bridge, indication-specific coverage and state Medicaid questions. Eligibility and authorization remain necessary; neither a prescription nor enrollment in a plan guarantees approval. For Medicaid members under 21, ask the plan about EPSDT and case-specific medical necessity². Federal employee plans have their own coverage requirements and authorization criteria¹.

What should you do if you're denied?

A denial is not necessarily final. Ask your prescriber's office for the specific denial reason and whether a letter of medical necessity — documenting your BMI, comorbidities, and prior lifestyle-intervention attempts — was included with the original request; incomplete documentation is a common, fixable cause of denial. If step therapy is the barrier, ask whether your history with a prior weight-management medication (including an older GLP-1 like liraglutide — see Saxenda vs Wegovy) can satisfy it. If your plan is employer-sponsored, ask HR directly whether anti-obesity medications are excluded by plan design, since some employer plans opt out entirely regardless of medical necessity — a fact worth confirming before spending months on appeals a plan design will never approve.

If coverage doesn't come through

Insurance denial does not mean the medication is out of reach — it means you're now pricing the cash-pay routes covered in what a GLP-1 costs without insurance: manufacturer self-pay for the brand product, or a verified compounded provider at a lower monthly cost. For the specific, payer-by-payer answer on Zepbound and Wegovy, see does insurance cover Zepbound or Wegovy. Price the real annual number for each route with our cost calculators rather than assuming insurance is the only affordable path. The coverage research behind this is indexed in our research library. Not medical advice — see our medical disclaimer; confirm your own plan's specific criteria with your insurer or benefits administrator.